Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen
- Generic Name
- Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen
- Brand Names
- Trumenba
- Drug Type
- Biotech
- Unique Ingredient Identifier
- 583WCD0IZI
- Background
Neisseria meningitidis serogroup B recombinant lp2086 a05 protein variant antigen is a sterile vaccine for intramuscular injection indicated for the active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. It is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily A and one from subfamily B (A05 and B01, respectively).
- Associated Conditions
- Infection caused by Neisseria Meningitidis Serogroup B
A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.
- Conditions
- GonorrheaChlamydiaMeningococcal Vaccines
- Interventions
- Biological: MenACWY Vaccine
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 999
- Registration Number
- NCT05873751
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 53
- Registration Number
- NCT04893811
- Locations
- 🇵🇱
IN-VIVO Sp. z o.o., Bydgoszcz, Poland
🇵🇱Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o., Krakow, Poland
🇵🇱WIP Warsaw IBD Point Profesor Kierkus, Warszawa, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.